Patents Assigned to Elan Pharma International Ltd.
-
Patent number: 9351902Abstract: A device for scar management includes an applicator head including a recess having a rotating means therein, a reservoir containing a silicone composition fluidly connected to the applicator head, and a metering valve fluidly connected to the reservoir. The composition has viscosity of 3,000 to 8,000 cps, and consists of a mixture of cyclopentasiloxane, dimethiconol, dimethicone, and dimethicone/vinyl dimethicone crosspolymer. A metered dose of the silicone composition is delivered from the reservoir to the applicator head upon the application of external pressure to the metering valve. The invention also relates to a method for scar management using such device by identifying a target skin area having a wound or scar, contacting the outward surface of the applicator head to the target skin area, massaging the rotating means of the applicator head on the target skin area, and applying the silicone composition to the target skin area via the rotating means.Type: GrantFiled: August 20, 2014Date of Patent: May 31, 2016Assignee: Elan Pharma International Ltd.Inventor: Jessica Rowen
-
Patent number: 7998507Abstract: Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.Type: GrantFiled: December 7, 2005Date of Patent: August 16, 2011Assignee: Elan Pharma International Ltd.Inventors: H. William Bosch, Greta G. Cary, Douglas C. Hovey, Rajeev A. Jain, Laura J. Kline, Elaine Merisko-Liversidge, Kevin D. Ostrander, Niels P. Ryde, Stephen B. Ruddy
-
Patent number: 7931917Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.Type: GrantFiled: May 23, 2007Date of Patent: April 26, 2011Assignees: Elan Pharma International, Ltd., Fournier Laboratories Ireland, Ltd.Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
-
Patent number: 7927627Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.Type: GrantFiled: May 23, 2007Date of Patent: April 19, 2011Assignees: Elan Pharma International, Ltd., Fournier Laboratories Ireland, Ltd.Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
-
Patent number: 7879360Abstract: The present invention is directed to nanoparticulate active agent compositions comprising at least one peptide as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.Type: GrantFiled: November 2, 2004Date of Patent: February 1, 2011Assignee: Elan Pharma International, Ltd.Inventors: James Cunningham, Elaine Merisko Liversidge
-
Patent number: 7850995Abstract: Bioadhesive nanoparticulate compositions, comprising active agent particles and one or more cationic surface stabilizers, are described. The cationic surface stabilizers prevent aggregation of the nanoparticles and increase bioadhesion of the nanoparticles to biological substrates, such as an insect, teeth, bone, nails, chitin, feathers, scales, mucous, skin, hair, plant tissue, etc. The particles may consist of pharmacologically active compounds (e.g., drug compounds for human or veterinary use), agricultural chemicals (pesticides, herbicides, fertilizers, and the like), cosmetic agents, consumer products (coloring agents, flavors, or fragrances), or other materials which function by interacting with biological substrates. In addition, the invention relates to methods of preparing and using such bioadhesive nanoparticulate compositions.Type: GrantFiled: September 11, 2007Date of Patent: December 14, 2010Assignee: Elan Pharma International, Ltd.Inventors: H. William Bosch, Eugene R. Cooper, Simon L. McGurk
-
Patent number: 7842232Abstract: The present invention relates to methods for sterilization of dispersions of one or more nanoparticulate active agents via gamma irradiation.Type: GrantFiled: May 24, 2004Date of Patent: November 30, 2010Assignee: Elan Pharma International, Ltd.Inventors: H. William Bosch, Janine Keller
-
Patent number: 7763278Abstract: The present invention is directed to nanoparticulate compositions comprising one or more polycosanols. The polycosanol particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of polycosanols and other cholesterol lowering agents are described and methods of using same are taught.Type: GrantFiled: June 10, 2003Date of Patent: July 27, 2010Assignee: Elan Pharma International Ltd.Inventors: Eugene R. Cooper, Laura Kline, Gary G. Liversidge, Niels P. Ryde
-
Patent number: 7713551Abstract: Disclosed is a solid or semi-solid gelatin nanoparticulate active agent dosage form comprising at least one nanoparticulate active agent and at least one gel forming substance which exhibits gelation sufficient to retain excess water in the solid or semi-solid gelatin form. The active agent particles have an effective average diameter prior to inclusion in the dosage form of less than about 2000 nm. The dosage form of the invention has the advantages of easy administration combined with rapid dissolution of the active agent following administration.Type: GrantFiled: September 11, 2003Date of Patent: May 11, 2010Assignee: Elan Pharma International Ltd.Inventors: Simon L. McGurk, David A. Czekai
-
Patent number: 7575184Abstract: A system for milling at least one material, e.g., a drug. The system includes a milling apparatus and at least one milling medium. The milling apparatus includes a chamber having a rotary milling head located in it. The milling head is rotated within the chamber by a magnetic drive system.Type: GrantFiled: August 3, 2007Date of Patent: August 18, 2009Assignee: Elan Pharma International Ltd.Inventors: Robert G. Reed, David Czekai
-
Patent number: 7521068Abstract: There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.Type: GrantFiled: November 12, 1998Date of Patent: April 21, 2009Assignee: Elan Pharma International Ltd.Inventors: H. William Bosch, Kevin D. Ostrander, Eugene R. Cooper
-
Patent number: 7390505Abstract: The present invention is directed to nanoparticulate compositions comprising topiramate. The topiramate particles of the composition have an effective average particle size of less than about 2 microns.Type: GrantFiled: January 30, 2004Date of Patent: June 24, 2008Assignee: Elan Pharma International, Ltd.Inventors: Evan Gustow, Tuula Ryde, Eugene R. Cooper
-
Patent number: 7320802Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.Type: GrantFiled: October 27, 2003Date of Patent: January 22, 2008Assignees: Elan Pharma International, Ltd., Fournier Laboratories Ireland Ltd.Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
-
Patent number: 7288267Abstract: Bioadhesive nanoparticulate compositions, comprising active agent particles and one or more cationic surface stabilizers, are described. The cationic surface stabilizers prevent aggregation of the nanoparticles and increase bioadhesion of the nanoparticles to biological substrates, such as an insect, teeth, bone, nails, chitin, feathers, scales, mucous, skin, hair, plant tissue, etc. The particles may consist of pharmacologically active compounds (e.g., drug compounds for human or veterinary use), agricultural chemicals (pesticides, herbicides, fertilizers, and the like), cosmetic agents, consumer products (coloring agents, flavors, or fragrances), or other materials which function by interacting with biological substrates. In addition, the invention relates to methods of preparing and using such bioadhesive nanoparticulate compositions.Type: GrantFiled: December 7, 2001Date of Patent: October 30, 2007Assignee: Elan Pharma International Ltd.Inventors: H. William Bosch, Eugene R. Cooper, Simon L. McGurk
-
Patent number: 7276249Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.Type: GrantFiled: May 23, 2003Date of Patent: October 2, 2007Assignees: Elan Pharma International, Ltd., Fournier Laboratories Ireland Ltd.Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
-
Patent number: 7244451Abstract: The present invention is directed to nanoparticulate compositions comprising a poorly soluble drug and at least one copolymer of vinyl pyrrolidone and vinyl acetate as a surface stabilizer adsorbed to the surface of the drug. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate composition of the invention, methods of making and using such nanoparticulate and pharmaceutical compositions.Type: GrantFiled: August 30, 2005Date of Patent: July 17, 2007Assignee: Elan Pharma International Ltd.Inventors: H. William Bosch, Niels P. Ryde
-
Patent number: 7198795Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.Type: GrantFiled: December 20, 2002Date of Patent: April 3, 2007Assignee: Elan Pharma International Ltd.Inventors: Eugene R. Cooper, John A. Bullock, John R. Chippari, John L. Schaefer, Rakesh A. Patel, Rajeev Jain, Joost Strasters, Niels P. Ryde, Stephen B. Ruddy
-
Patent number: 6969529Abstract: The present invention is directed to nanoparticulate compositions comprising a poorly soluble drug and at least one copolymer of vinyl pyrrolidone and vinyl acetate as a surface stabilizer adsorbed to the surface of the drug. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate composition of the invention, methods of making and using such nanoparticulate and pharmaceutical compositions.Type: GrantFiled: January 16, 2003Date of Patent: November 29, 2005Assignee: Elan Pharma International Ltd.Inventors: H. William Bosch, Niels P. Ryde
-
Patent number: 6908626Abstract: Disclosed are compositions exhibiting a combination of immediate release and controlled release characteristics. The compositions comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least one active ingredient having a microparticulate particle size.Type: GrantFiled: October 11, 2002Date of Patent: June 21, 2005Assignee: Elan Pharma International Ltd.Inventors: Eugene R. Cooper, Stephen B. Ruddy
-
Publication number: 20040258757Abstract: The present invention relates to liquid dosage compositions of stable nanoparticulate active agents. The liquid dosage compositions of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the active agent.Type: ApplicationFiled: July 16, 2003Publication date: December 23, 2004Applicant: Elan Pharma International, Ltd.Inventors: H. William Bosch, Matthew R. Hilborn, Douglas C. Hovey, Laura J. Kline, Robert W. Lee, John D. Pruitt, Niels P. Ryde, Tuula A. Ryde, Shuqian Xu